Dr. Keyvan Karkouti and I discussed the FARES-II trial. PCC is superior to FP for hemostasis in managing excessive bleeding among cardiac surgery ptS with coagulopathy. March 29, 2025 2025 | ACC | Cardiology | Trial | Video Disclosures: TBD Karkouti et al_ACC2025_LEX-211 slides Final (1)Download Article Navigation Dr. Marc Bonaca and I discussed the STRIDE trial. Semaglutide improves functional outcomes in DM pts with symptomatic PAD, addressing a critical unmet need. Dr. Hyo-Soo Kim and I discussed the HOST-BR trial on optimal DAPT duration and thrombosis-bleeding balance in ACS patients. 3-month DAPT reduced thrombosis vs. 1-month in high bleeding risk, and reduced bleeding vs. 12-month in low-risk patients
